Medtronic's Intrepid Valve Eliminates Mitral Regurgitation At 30 Days, Study Shows

• Medtronic plc (NYSE: MDT) announced early data for its self-expanding Intrepid transcatheter mitral valve replacement (TMVR) system for mitral valve regurgitation (MR) utilizing the transfemoral access route.

• Data from the first 15 patients enrolled in an Early Feasibility Study of the Intrepid Transfemoral System showed 100% survival and no stroke, a median procedure time of 46 minutes, and none/trace MR in all implanted patients at 30 days.

• The data were published simultaneously in the American College of Cardiology (JACC): Cardiovascular Intervention.

• Mitral regurgitation (MR) occurs when blood flows backward through the mitral valve and into the atrium when the left ventricle contracts.

• The Intrepid valve has been used to treat more than 350 patients as part of global clinical trials.

• The Intrepid TMVR system is only available for investigational use, and it is not approved outside of clinical studies.

• Related: Medtronic Touts 5-Year Data Of Self-Expanding TAVR Platform.

• Price Action: MDT shares closed at $122.98 on Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• Medtronic Touts 5-Year Data Of Self-Expanding TAVR Platform

• Medtronic To Face Class Action Suit From Canadian Users Of MiniMed Insulin Pumps

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.